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Letters to the Editor
Cardiovascular Mortality in
High-Risk Patients and T-786C
Polymorphism in Promoter
Region of the Endothelial Nitric
Oxide Synthase Gene
Rossi et al. (1) reported very interesting and intriguing results of
the first prospective study examining the possible effects of 2 single
nucleotide polymorphisms (SNP) in the endothelial nitric oxide
synthase (eNOS) gene (the T-786C SNP in the promoter region,
and the G894T SNP in exon 7) on cardiovascular mortality among
high-risk patients. Although no significant effects were found for
the G894T SNP, more cardiovascular deaths were found when
individuals with TT genotype for the T-786C SNP were com-
pared with CC  CT individuals (1). The significant effect of
T-786C SNP on cardiovascular mortality persisted even after
many confounding factors were taken into consideration. How-
ever, a significant number of individuals (32%) were on lipid-
lowering therapy at recruitment (1), and it is probable that an
increased proportion of these subjects may have received statins
thereafter.
Interestingly, although the T-786C SNP apparently does not
significantly affect nitric oxide (NO) availability (2,3), it may
modulate the responses to statins. In this regard, we have recently
reported that treatment with atorvastatin significantly increased
NO availability (measured as whole blood nitrite) in CC individ-
uals, but not in TT individuals (4), thus confirming previous
findings suggesting that statins may produce stronger effects on
NO availability in CC individuals compared with TT individ-
uals (5). In addition, atorvastatin significantly reduced the
concentrations of inflammatory markers in subjects with CC
(but not TT) genotype (6). Although these findings derive from
studies that included healthy individuals, they suggest that statins may
significantly modify the cardiovascular risk associated with the
T-786C SNP. Indeed, it is possible that treatment with statins
counteracts the effects associated with the T-786C SNP (4), thus
leading to apparently paradoxical results such as those reported by
Rossi et al. (1).
Figure 2 Contrast Left Ventriculography in the Right Anterior Oblique Projection
The left ventriculogram at end-diastole (A) and end-systole (B), showing apical ballooning and basal hyperkinesis.
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Effects of Endothelial
Nitric Oxide Synthase Gene
Polymorphisms on Oxidative
Stress, Inflammatory Status,
and Coronary Atherosclerosis: An
Example of a Transient Phenotype
In their recent study, Rossi et al. (1) showed that the T786C
polymorphism on the promoter region of the endothelial nitric
oxide synthase (eNOS) gene modifies redox-sensitive inflamma-
tory pathways, and may be a predictor for clinical outcome in
high-risk patients with coronary atherosclerosis. Although this
polymorphism was found to be in linkage disequilibrium with the
functional polymorphism G894T (D=  0.3), the latter had no
predictive value in this cohort, despite the results of a large
meta-analysis suggesting the opposite (2). However, the observa-
tion that the 894T/786T haplotype leads to a worse cardiovascular
death-free survival supports the hypothesis of a more complex
association between these polymorphisms and eNOS function.
We have recently shown (3) that the presence of the 894T allele
is associated with higher levels of oxidized low-density lipoprotein
and proinflammatory cytokines only under conditions of “biolog-
ical stress,” such as during the acute phase of myocardial infarction,
an effect not observed in the same subjects 1 year after the event,
or in healthy individuals. Moreover, the 894T allele seems to be
associated with impaired endothelial function in high-risk patients
(4) and in healthy smokers (5), but not in healthy, low-risk
individuals (5).
In the present study, Rossi et al. (1) actually introduce the
hypothesis that the previously observed transient effect of the 894T
allele on oxidative stress, inflammatory process, and endothelial
function (3–5) could actually be due to its linkage disequilibrium
with the 786T allele (which has been suggested to modify eNOS
expression). However, this could be due to the complex interaction
of both polymorphisms constituting the 894T/786T haplotype.
The combination of low eNOS expression (induced by the 786T
allele) and increased susceptibility of eNOS to proteolytic cleavage
(induced by the 894T allele) (6) could lead to a combined effect on
the associated phenotype of nitric oxide bioavailability, and the
subsequent alterations of oxidative stress and inflammatory status.
Therefore, further molecular studies are required to explore the
transient behavior of eNOS genotypes/haplotypes, leading to a
different phenotype, depending on the underlying disease state.
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Reply
To explain our (1) intriguing results on the effects of the T-786C (in
the promoter) and the G894T (in exon 7) single nucleotide polymor-
phisms (SNP) of the endothelial nitric oxide (NO) synthase (eNOS)
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